Rhythm Pharmaceuticals

OverviewSuggest Edit

Rhythm Pharmaceuticals is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.
TypePublic
Founded2008
HQBoston, US
Websiterhythmtx.com
Employee Ratings5

Latest Updates

Employees (est.) (Nov 2017)22(+23%)
Share Price (May 2019)$28.5 (+3%)

Key People/Management at Rhythm Pharmaceuticals

Keith Gottesdiener

Keith Gottesdiener

CEO

Rhythm Pharmaceuticals Office Locations

Rhythm Pharmaceuticals has an office in Boston
Boston, US (HQ)
Boston, MA, USA
Show all (1)

Rhythm Pharmaceuticals Financials and Metrics

Rhythm Pharmaceuticals Revenue

USD

Net income (Q3, 2017)

(10.0m)

EBIT (Q3, 2017)

(8.3m)

Market capitalization (22-May-2019)

980.6m

Closing stock price (22-May-2019)

28.5

Cash (30-Sep-2017)

27.9m
Rhythm Pharmaceuticals's current market capitalization is $980.6 m.
Annual
USDFY, 2015FY, 2016

General and administrative expense

3.4m6.3m

R&D expense

7.1m19.6m

Operating expense total

10.6m25.9m

EBIT

(10.6m)(25.9m)
Quarterly
USDQ3, 2016Q3, 2017

General and administrative expense

982.0k2.3m

R&D expense

5.4m6.0m

Operating expense total

6.4m8.3m

EBIT

(6.4m)(8.3m)
Annual
USDFY, 2015FY, 2016

Cash

34.9m6.5m

Prepaid Expenses

623.0k638.0k

Current Assets

35.5m11.2m

PP&E

17.0k930.0k
Quarterly
USDQ2, 2017Q3, 2017

Cash

8.7m27.9m

Prepaid Expenses

722.0k1.6m

Current Assets

18.5m32.0m

PP&E

822.0k845.0k
Annual
USDFY, 2015FY, 2016

Net Income

(11.1m)(25.9m)

Depreciation and Amortization

144.0k

Accounts Payable

893.0k467.0k

Cash From Operating Activities

(7.0m)(23.2m)
Quarterly
USDQ2, 2016Q3, 2016Q2, 2017Q3, 2017

Net Income

(11.1m)(17.5m)(13.2m)(23.2m)

Depreciation and Amortization

33.0k89.0k108.0k163.0k

Accounts Payable

882.0k(335.0k)(602.0k)830.0k

Cash From Operating Activities

(12.6m)(17.0m)(13.2m)(21.6m)
USDY, 2017

Financial Leverage

-0.7 x
Show all financial metrics

Rhythm Pharmaceuticals News and Updates

Rhythm Pharmaceuticals Reports First Quarter 2019 Financial Results

- Announced updated clinical data from Phase 2 basket study of setmelanotide in MC4R pathway heterozygous (HET) obesity, demonstrating consistent weight and hunger responses in patients with high-impact loss-of-function (LOF) variants -

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

BOSTON, March 08, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today reported financial results and provided a business updat…

Rhythm Pharmaceuticals Reports Third Quarter 2018 Financial Results

-- Presented Updated Data from Phase 2 Basket Studies in Bardet-Biedl Syndrome (BBS) and Alström Syndrome at the 57th Annual European Society for Pediatric Endocrinology (ESPE) Meeting -- -- Launched TEMPO Registry for Rare Genetic Disorders of Obesity --

Rhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical Officer

BOSTON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the appointment of Murray W. Stewart, D.M., F.R…

Rhythm Pharmaceuticals to Present at Morgan Stanley 16th Annual Global Healthcare Conference

BOSTON, Sept. 07, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Executive…

Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results

-- Completed Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Pro-opiomelanocortin (POMC) and Leptin Receptor (LEPR) Deficiency Obesity -- -- Announced New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Geneti…
Show more

Rhythm Pharmaceuticals Frequently Asked Questions

  • When was Rhythm Pharmaceuticals founded?

    Rhythm Pharmaceuticals was founded in 2008.

  • Who are Rhythm Pharmaceuticals key executives?

    Rhythm Pharmaceuticals's key executives are Keith Gottesdiener.

  • How many employees does Rhythm Pharmaceuticals have?

    Rhythm Pharmaceuticals has 22 employees.

  • Who are Rhythm Pharmaceuticals competitors?

    Competitors of Rhythm Pharmaceuticals include Shire, Otonomy and Biogen.

  • Where is Rhythm Pharmaceuticals headquarters?

    Rhythm Pharmaceuticals headquarters is located at Boston, MA, USA, Boston.

  • Where are Rhythm Pharmaceuticals offices?

    Rhythm Pharmaceuticals has an office in Boston.

  • How many offices does Rhythm Pharmaceuticals have?

    Rhythm Pharmaceuticals has 1 office.